RE:$TLTFF Feb1 till now Declining Volume Rising stock price. floatinketucky wrote
Bullish for sure.
Consider the Five year price range and what was not a factor in that price.
We never really knew if the FDA would grant a Phase 2 study. They did
We never really know if the FDA would grant a FTD. They did.
We never really knew if The FDA would consider BTD with 25 patients. They are.
And the price of the stock is not reflecting any of this.
Money is seeing this and the value at hand.
Is it too early to add to your list floatinketucky Shawn's remarks from the last NR of Feb. 24/2021
Shawn Shirazi, PhD, Chief Executive Officer, Theralase®, stated, "Each CSS Theralase launches for Study II will aid in our objective of enrolling and treating 10 patients in early 2021 to achieve a total of 25 patients for potential Breakthrough Designation Approval and approximately 75 to 100 additional patients in 2021 / 2022."